News and Treatment Updates
Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.
Press Release Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
Originally Published: 08/01/2022
Article Source: External Web Content
BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug...
Patients With MPNs Must Be Honest About Their Symptoms, Says Expert
Originally Published: 06/20/2022
Article Source: External Web Content
It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.
Because patients with essential thrombocythemia (ET) or polycythemia vera (PV) — rare types of blood cancers known as myeloproliferative neoplasms (MPNs) — experience a range of symptoms that can significantly impact their quality of life, it’s important that patients communicate what they’re experiencing with their health care team.
Symptoms may include fatigue, symptoms...
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
Originally Published: 06/02/2022
Article Source: External Web Content
June 2, 2022
- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –
- Omidubicel has Orphan Drug Designation and Breakthrough Therapy Designation -
BOSTON--(BUSINESS WIRE)--Jun. 2, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced completion of the rolling Biologics License...
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Originally Published: 05/25/2022
Article Source: External Web Content
BOSTON, May 25, 2022 – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed...
Spring MDS Update 2022
Originally Published: 05/01/2022
Article Source: MDS Update
The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator
Originally Published: 03/28/2022
Article Source: External Web Content
PURPOSE:
Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to become experts in their cancer. This combination of empowerment and expertise describes the new “e-patients.”
Article continues at link.
Living in an online world: Social media experiences of adolescents and young adults with cancer
Originally Published: 03/16/2022
Article Source: External Web Content
Abstract
Background
Despite widespread use, little is known about how adolescents and young adults (AYA) with cancer use social media (SM). This research characterized use and self-reported SM experiences among AYA with cancer.
Procedure
AYA, aged 12-26 years, receiving cancer care completed a mixed-methods survey regarding SM experiences. Clinical information was obtained from the electronic medical record. Data were analyzed with descriptive statistics, t tests, and qualitative content analysis.
Results
Thirty-nine AYA with average age 16 (SD = 3.2) years participated. Most were Caucasian...
Student view: Donor diversity saves lives
Originally Published: 03/16/2022
Article Source: External Web Content
Editor's note: Here's an update on Mychaela (see Stories of Hope)
Mychaela Lovelace is a sophomore at Michigan State University majoring in kinesiology in the College of Education, and is a scholar and mentor in the Dow STEM Scholars Program.
On April 1, 2008, at the age of 5 I was diagnosed with severe aplastic anemia, which is a rare condition that occurs when your body stops producing enough new blood cells. About two in every, 1 million people in the United States are diagnosed with the disease each year.
After being diagnosed, I knew, even at the young age of 5, that I was going to...
Seeing Cancer From All Sides: Richard M. Stone Is Giant of Cancer Care in Leukemia
Originally Published: 03/11/2022
Article Source: External Web Content
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research.
Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15. His father, Benjamin, developed kidney cancer when Stone was just 5 years old, and 10 years later, the disease metastasized and took the man’s life.
Stone says he went from being middle class to poor rapidly after his father died. “And that sort of gave me the incentive to work hard,” he said.
Stone was an only child...
MDS Update Winter 2022
Originally Published: 02/28/2022
Article Source: MDS Update
Please click on the link above to view the full update!